Stanford scientists have developed novel, inhibitory chimeric antigen receptor T cells (iCARs) based on immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing signaling domains that can inhibit standard activating CAR (aCARs) activity (see figure* below).
Researchers at Stanford University have discovered a way to enhance the effectiveness of CAR-T cell therapeutics through inducing a more memory-like phenotype.
Stanford Scientists have developed an innovative approach that enhances the antitumor efficacy of CAR T cells by overexpressing Adenosine Deaminase 1 (ADA), an enzyme responsible for metabolizing adenosine into inosine, to attenuate the immunosuppressive tumor microenvironment
Researchers at Stanford University have developed a method and composition of immunomodulatory compounds that prevent and reverse T cell exhaustion, improving on existing CAR T cell therapies.
There are several barriers to widespread use of CAR T-cell therapy. One of them is toxicity, primarily cytokine release syndrome (CRS) and neurologic toxicity, but also on-target off-tumor toxicity.
Researchers at Stanford have developed a method of culture media supplementation with inosine during the chimeric antigen receptor (CAR)-T cell manufacturing process which can alter and enhance CAR-T cell metabolism and anti-tumor functions.
Chimeric antigen receptor (CAR) T-cells targeting CD19 (or CAR19 T-cells) are an emerging, active therapy for patients with lymphomas. Despite high response rates to therapy, most patients will ultimately have disease progression after CAR19 T-cell therapy.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
A Stanford research team has patented methods that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Researchers at Stanford, led by Prof. Crystal Mackall and Prof. Jennifer R Cochran, have developed a unique approach to cancer treatment by tackling both the innate and adaptive immune systems.
Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.